Business Context and Reporting Period
Company: Abivax S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: June 29, 2026
Subject: Announcement of positive topline results from Part 2 of the Phase 3 ABTECT 44-week maintenance trial for obefazimod in moderate to severely active ulcerative colitis (UC).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory milestones. The Company anticipates reporting half-year 2026 financial results on September 21, 2026.
Material Changes and Clinical Results
The filing details significant clinical data from Part 2 of the Phase 3 maintenance trial, focusing on patients who were induction non-responders or relapsed during Part 1.
Efficacy in Induction Non-Responders (Week 44)
Continuous treatment with 50 mg obefazimod demonstrated the strongest outcomes:
- Clinical Remission: 37.2% (vs. 23.5% for 25 mg)
- Clinical Response: 61.5% (vs. 50.6% for 25 mg)
- Endoscopic Improvement: 48.0% (vs. 28.4% for 25 mg)
- Endoscopic Remission: 34.5% (vs. 22.2% for 25 mg)
Efficacy in Part 1 Relapsers
Re-treatment with 50 mg obefazimod showed potential to re-establish disease control:
- Placebo to 50 mg: 45.0% Clinical Remission; 69.7% Clinical Response.
- 25 mg to 50 mg: 45.5% Clinical Remission; 66.7% Clinical Response.
Safety Profile
No new safety patterns emerged. Key events included:
- Non-Melanoma Skin Cancers (NMSC): 4 total events (2 in 25 mg arm, 2 in 50 mg arm). All occurred in patients with established risk factors (e.g., advanced age, thiopurine use).
- Malignancies (Excluding NMSC): 2 events in the 50 mg arm (Myeloproliferative Neoplasm and Prostate Cancer), both deemed unrelated to obefazimod by investigators.
- Exposure-Adjusted Incidence Rates (EAIR): Rates for NMSC and malignancies in active treatment arms remained within the background reference range for UC patients based on published studies.
Guidance, Outlook, and Risks
Regulatory Path and Milestones
- NDA Submission: The Company remains on track to submit a New Drug Application (NDA) to the U.S. FDA in the fourth quarter of 2026.
- Financial Results: Half-year 2026 results expected September 21, 2026.
- Crohn's Disease: Topline results from the Phase 2b ENHANCE-CD induction trial expected in mid-2027.
Risks and Contingencies
The filing includes standard forward-looking statement disclaimers. Key risks include uncertainties in clinical development, regulatory decisions by the FDA or EMA regarding approval and labeling, and the availability of sufficient funding for operating expenses. Investors are cautioned that actual results may differ materially from projections.
Investor Verification Checklist
- NDA Timeline: Verify the Company's ability to submit the NDA in Q4 2026 as planned.
- Safety Data Review: Confirm the exposure-adjusted incidence rates for malignancies and NMSC against independent UC epidemiologic data.
- Financial Health: Monitor the upcoming September 21, 2026, financial report for cash runway and burn rate given the pre-revenue status.
- Regulatory Feedback: Watch for any FDA feedback or requests for additional data following the NDA submission.
- Crohn's Disease Pipeline: Track progress of the ENHANCE-CD trial for potential expansion of the drug's label.